Suppr超能文献

ST 段抬高型心肌梗死患者入院时高敏肌钙蛋白的预后价值。

Prognostic value of admission high-sensitivity troponin in patients with ST-elevation myocardial infarction.

机构信息

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

School of Biomedical Engineering and Imaging Sciences, King's College, London, UK.

出版信息

Heart. 2021 Dec;107(23):1881-1888. doi: 10.1136/heartjnl-2021-319225. Epub 2021 Sep 20.

Abstract

BACKGROUND AND AIM

Although the diagnostic usefulness of high-sensitivity cardiac troponin T (hs-cTnT) is well established in ST-segment elevation myocardial infarction (STEMI), its prognostic relevance in risk stratification of patients with STEMI remains obscure. This study sought to determine the prognostic value of pre-reperfusion (admission) and post-reperfusion (12-hour) hs-cTnT in patients with STEMI treated with primary percutaneous coronary intervention (PPCI).

METHODS

Retrospective observational longitudinal study including consecutive patients with STEMI treated with PPCI at a university hospital in the northeast of England. hs-cTnT was measured at admission to the catheterisation laboratory and 12 hours after PPCI. Clinical, procedural and laboratory data were prospectively collected during patient hospitalisation (June 2010-December 2014). Mortality data were obtained from the UK Office of National Statistics. The study endpoints were in-hospital and overall mortality.

RESULTS

A total of 3113 patients were included. Median follow-up was 53 months. Admission hs-cTnT >515 ng/L (fourth quartile) was independently associated with in-hospital mortality (HR=2.53 per highest to lower quartiles; 95% CI: 1.32 to 4.85; p=0.005) after multivariable adjustment for a clinical model of mortality prediction. Likewise, admission hs-cTnT >515 ng/L independently predicted overall mortality (HR=1.27 per highest to lower quartiles; 95% CI: 1.02 to 1.59; p=0.029). Admission hs-cTnT correctly reclassified risk for in-hospital death (net reclassification index (NRI)=0.588, p<0.001) and overall mortality (NRI=0.178, p=0.001). Conversely, 12-hour hs-cTnT was not independently associated with mortality.

CONCLUSION

Admission, but not 12-hour post-reperfusion, hs-cTnT predicts mortality and improves risk stratification in the PPCI era. These results support a prognostic role for admission hs-cTnT while challenge the cost-effectiveness of routine 12-hour hs-cTnT measurements in patients with STEMI.

摘要

背景和目的

高敏肌钙蛋白 T(hs-cTnT)在 ST 段抬高型心肌梗死(STEMI)中的诊断价值已得到充分证实,但在 STEMI 患者的风险分层中的预后相关性仍不清楚。本研究旨在确定在接受直接经皮冠状动脉介入治疗(PPCI)的 STEMI 患者中,再灌注前(入院时)和再灌注后(12 小时)hs-cTnT 的预后价值。

方法

这是一项回顾性观察性纵向研究,纳入了在英格兰东北部一所大学医院接受 PPCI 治疗的连续 STEMI 患者。hs-cTnT 在入导管实验室时和 PPCI 后 12 小时进行测量。在患者住院期间(2010 年 6 月至 2014 年 12 月)前瞻性收集临床、手术和实验室数据。死亡率数据从英国国家统计局获得。研究终点为院内和总死亡率。

结果

共纳入 3113 例患者。中位随访时间为 53 个月。多变量调整后,入院时 hs-cTnT>515ng/L(第四四分位数)与院内死亡率独立相关(HR=2.53,四分位数比 1.32 至 4.85;p=0.005)。同样,入院时 hs-cTnT>515ng/L 也独立预测总体死亡率(HR=1.27,四分位数比 1.02 至 1.59;p=0.029)。入院时 hs-cTnT 可正确重新分类院内死亡风险(净重新分类指数(NRI)=0.588,p<0.001)和总体死亡率(NRI=0.178,p=0.001)。相反,12 小时 hs-cTnT 与死亡率无关。

结论

入院时而非再灌注后 12 小时 hs-cTnT 可预测死亡率,并改善 PPCI 时代的风险分层。这些结果支持入院时 hs-cTnT 的预后作用,但对 STEMI 患者常规 12 小时 hs-cTnT 测量的成本效益提出了挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验